Cite
SILAC-based chemoproteomics reveals a neoligan analogue as an anti-inflammatory agent targeting IRGM to ameliorate cytokine storm.
MLA
Zhang, Jichao, et al. “SILAC-Based Chemoproteomics Reveals a Neoligan Analogue as an Anti-Inflammatory Agent Targeting IRGM to Ameliorate Cytokine Storm.” European Journal of Medicinal Chemistry, vol. 241, Nov. 2022, p. N.PAG. EBSCOhost, https://doi.org/10.1016/j.ejmech.2022.114659.
APA
Zhang, J., Li, Y., Meng, G., Lu, K., Yan, J., Wu, J., Li, P., Luo, L., Chen, X., Zhao, X., & Qiu, F. (2022). SILAC-based chemoproteomics reveals a neoligan analogue as an anti-inflammatory agent targeting IRGM to ameliorate cytokine storm. European Journal of Medicinal Chemistry, 241, N.PAG. https://doi.org/10.1016/j.ejmech.2022.114659
Chicago
Zhang, Jichao, Yang Li, Guibing Meng, Kui Lu, Jiankun Yan, Jiangpeng Wu, Pengyan Li, et al. 2022. “SILAC-Based Chemoproteomics Reveals a Neoligan Analogue as an Anti-Inflammatory Agent Targeting IRGM to Ameliorate Cytokine Storm.” European Journal of Medicinal Chemistry 241 (November): N.PAG. doi:10.1016/j.ejmech.2022.114659.